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be investigated by pooling RCT and RWE data in a response surface analysis. The 
maximum effect may be established in a region of treatment/dose combination 
not yet studied in a randomised setting. This methodology can also be used to 
determine which combination of patient’s characteristics will result in the most 
optimal effect for each (line) of therapy and as a result, provide targeted treatment 
for (groups of) patients based on their baseline characteristics. Further work could 
involve optimizing the response in higher dimensions.
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Objectives: To determine which clinical outcomes, both “soft” and “hard”, are cur-
rently used in phase III treatment studies for hematoncologic diseases, and what 
proportion of them use overall survival (OS) as the primary outcome. MethOds: 
Through a search in PubMed, we identified and analyzed all randomized clinical 
trials published in the last 10 years, for de novo treatments in adults. Results: 
The initial search yielded 310 references, from which 90 trials were selected. The 
most studied disease was multiple myeloma, with 29 studies, followed by non-
Hodgkin lymphoma with 26. The others were acute myeloid leukemia 12, chronic 
lymphocytic leukemia 10, chronic myeloid leukemia 8, myelodysplastic syndromes 
3 and Hodgkin lymphoma 2. The 90 studies had a total of 108 “primary” and 252 
“secondary” outcomes; 20 studies (22%) had OS as primary endpoint (though only 
3 of them reached statistical significance), in over 37 (41%) OS was grouped with 
other outcomes to form a composite endpoint. In 55 studies (61%) overall survival 
was a secondary outcome. Quality of life was a “secondary” outcome in 10 stud-
ies. cOnclusiOns: Although OS is the gold standard in cancer therapy, grouped 
outcomes, or others intermediate outcomes, such as progression-free survival or 
paraclinical indicators of disease activity are more frequently used and may be good 
predictors. Intermediate outcomes require smaller sample sizes and less follow-up. 
Their capacity to predict OS (or, indeed, quality of life) should be carefully assessed. 
Only in the most aggressive forms of cancer is routine use of OS survival justified 
as the primary endpoint.
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Objectives: The objectives of this study were: 1) to compare low back pain (LBP) 
patient valuations with those of the general population, 2) to explore how various 
aspects of health-related quality of life as measured by the EQ-5D-3L impact LBP 
patient valuations, and 3) to explore the implications of the choice of valuation 
method for cost-utility analyses (CUAs). MethOds: Data of 483 LBP patients who 
participated in a 52-week Dutch randomized controlled trial were used. Outcome 
measures included the EQ-5D-3L, EQ-VAS, and societal costs. Patient valuations were 
derived from the EQ-VAS. Population valuations were derived using a Dutch VAS-
based EQ-5D-3L value set. The difference and agreement between both valuations 
were assessed using t-tests and intraclass correlation coefficients (ICC), respectively. 
An ordinary least square linear regression model was constructed to explore how 
various aspects of health-related quality of life as measured by the ED-5D-3L impact 
LBP patient valuations. Moreover, two CUAs were performed; one using patient 
valuations and one using population valuations. Results: Patients valued their 
health state 0.098 (95%CI: 0.082 to 0.115) points higher compared with the general 
population. The two valuations had an ICC of 0.544. The regression model indicated 
that 22.2% of the variance in patient valuations was explained by the LBP patients’ 
EQ-5D-3L health state (R2= 0.222), and that LBP patients gave the most weight to 
the anxiety/depression dimension. In the CUA, the maximum probability of cost-
effectiveness was found to be lower when patient (i.e. 0.28) instead of population 
valuations (i.e. 0.38) were used. cOnclusiOns: This study demonstrated that LBP 
patients value their health state higher than members of the general population and 
that the choice of valuation method could have important implications for CUAs. As 
consensus does currently not exist regarding the question of ‘whose values count’, 
researchers are encouraged to explore these implications using sensitivity analyses.
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Objectives: Stochastic multicriteria acceptability analysis (SMAA) is a power-
ful tool for health technology benefit-risk assessment when health outcomes are 
assessed according to multicriteria and both the outcomes and preference weights 
are subject to uncertainty, in particular with missing weight information. We pro-
pose using a Bayesian approach for SMAA to provide an alternative or supplement 
to the standard SMAA. It can estimate the posterior distributions of decision maker’s 
preference weights on multicriteria, had he/she prefer treatment A over B. Given 
the preference on previous treatments and safety and efficacy profiles, it can also 
predict the decision maker’s preference on a new treatment. MethOds: The SMAA 
method was adapted to fit into the Bayesian framework, assuming that the weights 
follow a Dirichlet prior distribution. A simple Monte-Carlo procedure was developed 
to calculate the posterior distribution for the weights, and Bayesian estimates of 
major measures in standard SMAA were derived. An algorithm was also developed 
to predict future rankings. The method allows using informative, non-informative 
or hierarchical priors, and can be extended to other SMAA methods such as that 
based the prospect theory (SMAA-P). This method is applied to the assessment of 
in THIN from 2% to 13%. This work shows the potential for under-reporting of PSS 
in primary care data, and provides a method for improved identification of cases 
and control records for future studies.
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Objectives: The therapeutic options for Multiple Sclerosis(MS) improved over the 
past years with the approval of new substances. Therapeutic optimization must take 
into account an individualized assessment of clinical and imaging disease activity, 
treatment response as well as identifying early risk factors for treatment failure. 
This study will address by assess this issue by 1. Assess the utility of a tool that 
helps to identify patients with ongoing disease activity 2. The systematic collection 
of a broader set of functional domains to explore their potential to be used as a 
predictive measure of future disease activity or treatment response. 3. Evaluate the 
clinical course of patients according to NEDA-4 parameter as measured by relapse 
activity, disability progression, MRI activity and change in brain volume. 4. Assess 
the therapeutic effectiveness of switching to fingolimod if the patients are assessed 
to be failing their current first line therapy. MethOds: 1500 patients are planned to 
be included in this observational study. All patients with active disease as defined by 
Lublin et al., 2014, undergo a first evaluation of the patient status. Patients switching 
to fingolimod are followed for 3 years. The study set up and documentation param-
eters are based on three bullets: 1. Optimal patient management in daily clinical 
practice using the patient management system MSDS3D 2. State of the art evalua-
tion of the patient status using the MS-disease activity measurement tool 3. Multiple 
sclerosis optimized MRI-acquisition and analysis by central MRI-reading Results: 
and cOnclusiOns: PANGAEA 2.0 will give important insights on the predictive 
value of proposed treatment algorithms like the Lublin criteria and the modified Rio 
Score as well as the principle of NEDA (no evidence of disease activity) -4. It will also 
evaluate the benefit of a collection of a broad range of outcome parameter based on 
functional domains from a patient and physician perspective on therapy decisions.
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Objectives: Syntheses of time-to-event data often rely on published hazard 
ratios (HR) therefore assuming proportional hazards (PH). Methods now exist to 
reconstruct individual patient data (IPD) from published Kaplan-Meier (KM) plots. 
This enables the PH assumption to be formally tested, and a time ratio (TR) to 
be estimated as an alternative measure of relative treatment effect. While TRs do 
not require the PH assumption, these are rarely used in evidence synthesis. We 
compared TRs with HRs to demonstrate their ease of interpretation and transpar-
ency. MethOds: Relative treatment effect measures HRs and TRs were compared 
in terms of: scale, underlying assumptions, interpretation, availability in published 
literature and derivation. Results: HRs act on the log-hazard scale representing 
the ratio of hazards for treatment vs. control. TRs act on the log-failure time scale, 
representing the ratio of failure times for treatment vs. control. A HR< 1 represents 
a decrease in the event hazard whilst a TR< 1 represents an acceleration in time-
to-event, with treatment. The inverse of the TR, referred to as the acceleration fac-
tor (AF), therefore represents the same direction of benefit as for HRs. For TR= 2, 
AF= 0.5, the time-to-event for treatment is two times that for control. HRs are com-
monly reported to summarise the average relative treatment effect. TRs are rarely 
reported and hence less familiar to clinicians, but can be validated against any ratio 
of published survival times. cOnclusiOns: Relative treatment effects expressed 
as TRs are not commonly utilised in evidence synthesis due to unfamiliarity around 
interpretation and lack of availability in the published literature. When converted 
to AFs, TRs have a similar interpretation to HRs and can be estimated from IPD and 
published KM data. Therefore, evidence synthesis should no longer rely on published 
HRs as the measure of relative treatment effect when the PH assumption is violated.
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Objectives: Due to high costs, randomised clinical trials (RCTs) typically do not 
include a wide variety of doses and treatments within a single trial. Real-world 
evidence (RWE) can be used to fill the gaps left by treatment arms or doses not 
studied in first or second line RCTs. This is illustrated in rheumatoid arthritis (RA). 
The combined evidence can allow for investigating the area of dosing that can only 
be studied when all evidence is included. This may impact future dosing strategies 
that could result in approval of treatment (combinations) that may not have been 
studied otherwise but could substantially benefit patients with RA. MethOds: 
RCT and RWE data was combined in a network meta-analysis (NMA) to investigate 
treatment effects in patients with RA. Response surface methods were used to 
investigate the three dimensional surface of the observed effects as a function of 
doses for each pair of treatments. Optimization methods were used to establish the 
optimal treatment/dose region in patients with RA. Results: Results showed that 
including RWE has increased the totality of evidence with reduced uncertainty in 
first and second line treatment effects in patients with RA. The greatest evidence 
of effect was observed in a treatment/dose combination region not yet studied in 
RCTs cOnclusiOns: The optimal treatment regimen for patients with RA can 
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perspective was adapted and all costs were adjusted to British pounds in 2014 
value. Results: The mean survival of 311 AML patients was 1.2 years. The aver-
age inpatient costs and standard deviations over a follow-up period ranging from 
7 to 10 years were £38,532 (SD: £44,986), £32,115 (SD: £34,293), and £28,662 (SD: 
£33,298) for bottom-up costing, reference costs, and tariff costings respectively. 
These differences mainly reflect variations in first-line and second-line treatment 
costs (p< 0.001); while during remission, the cost estimates from the three meth-
ods were identical. cOnclusiOns: This study demonstrates that costing methods 
can generate substantially different cost estimates. Hence, decision makers need 
to interpret cost outcomes cautiously, taking account of the assumptions made.
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Objectives: In economic analyses, the size (volume per vial) of pharmaceutical 
products is usually taken as a fixed quantity. However, whilst the product is in devel-
opment, there is scope for the size to be altered. The objective of this study was to 
examine how product sizes might be optimised for maximum efficiency. MethOds: 
Four drugs available in two product sizes were chosen as examples: pemetrexed, 
cetuximab, panitumumab and belimumab. Drug costs per administration were 
estimated based on general population weight and body surface area data from 
the Health Survey for England, using the most efficient combinations of the two 
available vial sizes. The sizes of the two vials were varied simultaneously to identify 
the lowest average costs achievable. Results: Generally, smaller vials were associ-
ated with less wastage and lower costs. Within the size ranges analysed, the cost 
per administration could be reduced by an average of 4.4% (range: 1.12% to 6.39%). 
Over 1 year on treatment, this represents an average potential saving of £1,892 
(range: £120 to £3,289). However, this was associated with an increased number of 
vials per dose. cOnclusiOns: The cost effectiveness of new medicines could be 
enhanced by better planning in the manufacturing process and more efficiently 
sized vials. Costs were generally greater when the large vial was a multiple of the 
smaller vial (which is the case in three of the four example drugs). Non-divisible 
pairs are associated with more precise dosing and less wastage, as a greater number 
of unique quantities can be formed with same numbers of vials. Optimal vial sizing 
could reduce costs for health systems, improving patient access to new medicines 
as a consequence. Increases in the number of vials per dose may impact the time 
and cost of preparation, but additional costs may be offset by savings from reduc-
tions in wastage.
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Objectives: Cost analysis is an essential component of health economic evalu-
ation. However, cost data are often incomplete due to loss of follow-up or admin-
istrative termination. Ignoring censored data could lead to biased cost results. 
Over the decades, many statistical methods for censored cost data have been pro-
posed. However, studies on method comparison and appropriate application in 
clinical settings are limited. The aim of this study is to compare such methods and 
assess their accuracies in a population of patients with acute myeloid leukaemia 
(AML). MethOds: Data were sourced from Haematological Malignancy Research 
Network (www.hmrn.org), an established UK population-based registry, and cost 
data were derived from linked Hospital Episode Statistics (HES). All adults (≥ 18) in 
the network newly diagnosed with AML from September 2004 to August 2007 were 
included (n= 311) and followed until August 2014. Data were censored in 2008, 2010 
and 2012, accordingly cost analyses were undertaken for a minimum follow-up 
period of 1, 3 and 5 years respectively. Seven common methods were used to predict 
mean costs: naïve approaches (full-sample and uncensored cases), Lin’s 2007a, Lin’s 
2007b, Bang and Tsaitis, Lin’s regression and phase-based costing methods. All costs 
were adjusted to British pounds in 2014 value. Results: The true lifetime cost was 
£32,115 per patient. When censored in 2008, the estimate from Bang and Tsaitis 
method was the closest prediction (£30,536). When censored in 2010 and 2012, full-
case naïve and phase-based methods provided more accurate estimates (£31,486 
and £31,501 respectively). cOnclusiOns: The study shows that cost estimations 
vary with the method chosen and the duration of follow-up in the presence of cen-
soring. Compared to the true lifetime cost, the phase-base censoring method with a 
minimum 3-year follow-up would yield the most accurate cost estimation. Further 
work on other cancers are needed to confirm the generalizability of these results.
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Objectives: Centrifugation (Cf) is the standard method of fat processing but is 
cumbersome and time consuming, especially when large volumes are processed. A 
new autologous fat processing system (Rv) that incorporates fat harvesting and pro-
cessing in a single unit offers a simple, more efficient system. This study compared 
the efficiency and economics of using Rv with CF in terms of fat grafting and operat-
ing room (OR) costs. MethOds: Data were collected over 2 years from consecutive 
breast surgery patients undergoing autologous fat grafting: January to December 
2012 with the Cf method and January to December 2013 with Rv method. The volume 
of fat harvested, volume of fat injected after processing, and time taken to complete 
fat grafting (from harvest to injection) were determined. Standard OR costs ($15-$20 
efficacy and safety profiles for published data on antidepressants fluoxetine and 
venlafaxine vs placebo and is compared to standard SMAA results. Results: The 
results showed that, with a non-informative Dirichlet prior, the posterior mean 
weights for given rankings were similar to the central weight vectors of the standard 
SMAA, so were some other comparable measures such as the rank acceptability 
index and confidence factor cOnclusiOns: The Bayesian SMAA has a number of 
advantages inherited from Bayesian decision analysis. The Bayesian estimates for 
key SMAA measures are similar to those of the standard SMAA. But it offers more 
options and flexibilities than the standard SMAA, and its implementation is easier.
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Objectives: The objective was to conduct a Bayesian multivariate network meta-
analysis (NMA) to take into account the correlation between three outcome meas-
ures assessing glycaemic control for the monotherapy treatments of type 2 diabetes 
mellitus (T2DM). MethOds: A systematic literature review was conducted to iden-
tify relevant randomised clinical trials. The efficacy of T2DM treatments on glycae-
mic control was assessed using the change in HbA1c from baseline, the change in 
fasting plasma glucose (FPG) from baseline or the proportion of patients reaching 
HbA1c < 7%. A Bayesian multivariate NMA accounting for the correlation between 
outcomes was conducted to model these three outcomes simultaneously and results 
were compared to the estimates from the three univariate NMAs. Interpretation of 
results was based on absolute differences/ratios and surface under the cumula-
tive ranking curve (SUCRA). Results: A total of 40 studies were included in the 
analysis, all of them reported results in terms of HbA1c change from baseline, 36 
for FPG and 22 for the proportion of patients reaching HbA1c < 7%. Results for the 
analysis of glycaemic control from the multivariate NMA were overall consistent 
with the three univariate NMAs in terms of ranking of treatments based on the 
SUCRA and point estimates were comparable. Using the multivariate NMA, results 
for the proportion of patients reaching HbA1c < 7% were available for sulfonylureas, 
while no data on sulfonylureas were published for this outcome. Moreover, with the 
multivariate NMA, standard deviations were slightly lower compared to the univari-
ate ones. cOnclusiOns: This multivariate network meta-analysis of treatments 
in T2DM provided more precise estimates than separate univariate NMAs on gly-
caemic control. It enabled estimations of treatment effect for all comparators on all 
endpoints of interest including the ones for which data were not publicly available.
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Objectives: Indirect Treatment Comparisons (ITC) are used to contrast the effec-
tiveness of two or more treatments, and are usually undertaken in the absence of 
head-to-head information. However, these indirect comparisons are less effective 
in situations where baseline patient characteristics (e.g. age, disease duration) dif-
fer between studies. Any clinically meaningful variation in these characteristics 
between the studies should be adjusted for in the statistical analyses in order to 
arrive at less biased estimates of the treatment differences. At present, many ITCs 
use a comparison of a sponsor’s Individual Patient Data (IPD) with study-level sum-
mary information (typically means and SDs) from their competitors’ studies. Various 
methods currently exist which allow for the matching between studies of the base-
line characteristics means, but crucially not their variances. MethOds: We outline 
a novel approach which allows for the matching of both means and variances across 
multiple baseline patient characteristics. Our approach involves fitting higher-order 
polynomials separately to each of the baseline parameters with the aim of estimat-
ing a single weight for each individual patient. The weighted means and variances 
of the IPD are then compared with the (target) summary-level data. Simulation 
is used in order to arrive at the combination of polynomial functions which give 
the ‘best fit’. Results: The method is highlighted with a case study of anti-VEGF 
therapies in the treatment of visual impairment due to diabetic macular edema. Our 
proposed method successfully matches both the means and variances across three 
important predictors of post-baseline changes in visual acuity. cOnclusiOns: The 
ability to match IPD variability with study-level summary variability is critical in 
order to accurately estimate the statistical significance of treatment differences. To 
our knowledge, current comparative effectiveness methods fail to do so - our novel 
approach provides a possible solution to this problem.
ReseaRcH On MetHOds – cost Methods
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Objectives: Cost is an essential part of health economic evaluation. However, 
no set standard for costing has been suggested/proposed yet, and the impact of 
using different methods remains unclear. The aim of this study is to compare cost 
estimates from different costing methods and assess their impacts. MethOds: All 
adults (> 18) newly diagnosed with acute myeloid leukaemia between September 
2004 and August 2007 in the Haematological Malignancy Research Network (HMRN, 
www.hmrn.org, an established UK population-based registry) were included and 
followed until August 2014. Three costing methods were applied to the treatment 
pathways. One was a bottom-up costing, for which cost data were obtained directly 
from treating hospitals; and the other two were top-down costings that used refer-
ence costs and tariffs obtained from UK Hospital Episode Statistics (HES). The NHS 
